JP2025512062A - 補体阻害ハイブリッドタンパク質 - Google Patents

補体阻害ハイブリッドタンパク質 Download PDF

Info

Publication number
JP2025512062A
JP2025512062A JP2024560447A JP2024560447A JP2025512062A JP 2025512062 A JP2025512062 A JP 2025512062A JP 2024560447 A JP2024560447 A JP 2024560447A JP 2024560447 A JP2024560447 A JP 2024560447A JP 2025512062 A JP2025512062 A JP 2025512062A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
protein
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512062A5 (enExample
Inventor
ハイリー マー
ホン リウ
Original Assignee
ロンバイオ ファーマ（スーチョウ）カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロンバイオ ファーマ（スーチョウ）カンパニー，リミティド filed Critical ロンバイオ ファーマ（スーチョウ）カンパニー，リミティド
Publication of JP2025512062A publication Critical patent/JP2025512062A/ja
Publication of JP2025512062A5 publication Critical patent/JP2025512062A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024560447A 2022-04-11 2023-04-06 補体阻害ハイブリッドタンパク質 Pending JP2025512062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210374811.2 2022-04-11
CN202210374811 2022-04-11
PCT/CN2023/086593 WO2023197930A1 (zh) 2022-04-11 2023-04-06 补体抑制杂合蛋白

Publications (2)

Publication Number Publication Date
JP2025512062A true JP2025512062A (ja) 2025-04-16
JP2025512062A5 JP2025512062A5 (enExample) 2026-04-14

Family

ID=88312629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560447A Pending JP2025512062A (ja) 2022-04-11 2023-04-06 補体阻害ハイブリッドタンパク質

Country Status (6)

Country Link
US (1) US20250257106A1 (enExample)
EP (1) EP4509521A4 (enExample)
JP (1) JP2025512062A (enExample)
KR (1) KR20250004744A (enExample)
CN (1) CN116891533A (enExample)
WO (1) WO2023197930A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
EP4715959A1 (en) 2024-02-29 2026-03-25 LG Energy Solution, Ltd. Method for regenerating cathode active material and regenerated cathode active material manufactured therefrom

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3066699A (en) * 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
US9540626B2 (en) * 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201706808D0 (en) * 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
EP3958901A4 (en) * 2019-04-24 2023-07-19 The Trustees of the University of Pennsylvania BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질

Also Published As

Publication number Publication date
EP4509521A4 (en) 2026-04-15
CN116891533A (zh) 2023-10-17
EP4509521A1 (en) 2025-02-19
US20250257106A1 (en) 2025-08-14
WO2023197930A9 (zh) 2024-01-11
KR20250004744A (ko) 2025-01-08
WO2023197930A1 (zh) 2023-10-19

Similar Documents

Publication Publication Date Title
US11001822B2 (en) Complement factor B analogs and their uses
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
JP6771568B2 (ja) 補体活性化を抑制するポリペプチド
JP7505980B2 (ja) Ｃ３ｂ結合ポリペプチド
CN109535243B (zh) 人肝细胞生长因子突变体及其应用
JP2025512062A (ja) 補体阻害ハイブリッドタンパク質
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
EP4714979A1 (en) Biased complement inhibitory hybrid protein
CN118955727A (zh) 偏向性补体抑制杂合蛋白
WO2010102380A1 (en) Potent vegf antagonists
CN113861291A (zh) VEGF-trap多肽及其应用
CN115551529A (zh) 增强房水流出并降低眼内压的方法
NZ616479B2 (en) Complement factor b analogs and their uses
HK1190076B (en) Complement factor b analogs and their uses
HK1190076A (en) Complement factor b analogs and their uses
HK1037679A (en) Vascular endothelial growth factor 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260406